Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Bottom Line: M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1, with mean values numerically better at subsequent cycles; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant.The majority of HRQoL scores were better with sunitinib versus IFN-α for the same CTCAE fatigue grade.Patients reported worse fatigue during the first sunitinib cycle.
Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.Show MeSH
Related in: MedlinePlus
Mentions: As previously reported,6,14 HRQoL was assessed during the study using 3 psychometrically tested patient self-reported questionnaires: the Functional Assessment of Cancer Therapy-Kidney Symptom Index–15-item (FKSI-15) (Fig. 1),15 the Functional Assessment of Cancer Therapy-General (FACT-G),16 and the EuroQoL Group's 5-dimension (EQ-5D) questionnaire.17 Patients completed the questionnaires on days 1 and 28 of each treatment cycle (reflecting sunitinib's intermittent treatment schedule) to measure HRQoL across the full course of therapy, both during active treatment and after a treatment break, and at the end of treatment or study withdrawal. HRQoL scores were averaged for each patient by cycle.
Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.